Patient enrollment started in Ph 3 Trial of ACT001 in SCLC patients with Brain Mets
Accendatech Co., Ltd, a clinical-stage biotech company developing natural compound-based small molecule drugs with unique pharmacological properties announced the enrollment of first small cell lung cancer patient with brain metastasis this month for the pivotal phase 3 study in China (CTR20253399). The initiation of phase 3 trial is based on encouraging intracranial tumor response and overall survival signal from a phase 2b ACT001-CN-051 study which were released during 2025 SNO/ASCO conference held in Baltimore, MD in August, 2025. The topline data is expected to be published in a peer-reviewed journal.
Share:
More News
“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies
AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most
“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT
“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a